## Kenneth M Boucher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8537489/publications.pdf

Version: 2024-02-01

72 papers 3,378 citations

147801 31 h-index 56 g-index

74 all docs

74 docs citations

74 times ranked 6761 citing authors

#	Article	IF	Citations
1	A Randomized Double-blind Placebo-controlled Trial of Oral Aspirin for Protection of Melanocytic Nevi Against UV-induced DNA Damage. Cancer Prevention Research, 2022, 15, 129-138.	1.5	1
2	Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage InÂVivo. Journal of Investigative Dermatology, 2021, 141, 132-141.e3.	0.7	18
3	Low accuracy of self-reported family history of melanoma in high-risk patients. Familial Cancer, 2021, 20, 41-48.	1.9	3
4	A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 2021, 21, 510.	2.6	21
5	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 2021, 26, 1006-e2129.	3.7	13
6	A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors. Blood, 2021, 138, 143-143.	1.4	5
7	Distinct Molecular Phenotype of Sporadic Colorectal Cancers Among Young Patients Based on Multiomics Analysis. Gastroenterology, 2020, 158, 1155-1158.e2.	1.3	42
8	Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Melanoma Research, 2020, 30, 247-251.	1.2	5
9	Multi-omics Analysis Reveals Adipose–tumor Crosstalk in Patients with Colorectal Cancer. Cancer Prevention Research, 2020, 13, 817-828.	1.5	19
10	Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	7.0	45
11	ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Pharmaceuticals, 2020, 13, 7.	3.8	8
12	Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. Journal of Dermatology, 2020, 47, 342-347.	1.2	12
13	Two integrated and highly predictive functional analysis-based procedures for the classification of MSH6 variants in Lynch syndrome. Genetics in Medicine, 2020, 22, 847-856.	2.4	16
14	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 2104-2110.	7.0	15
15	AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Molecular Cancer Research, 2019, 17, 1787-1800.	3.4	46
16	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 3466-3478.	0.9	32
17	Powering a prospective melanoma chemoprevention trial in highâ€risk cohorts. International Journal of Dermatology, 2019, 58, e232-e234.	1.0	3
18	Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs, 2019, 37, 482-489.	2.6	17

#	Article	IF	CITATIONS
19	A functional assay–based procedure to classify mismatch repair gene variants in Lynch syndrome. Genetics in Medicine, 2019, 21, 1486-1496.	2.4	36
20	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e169-e172.	1.9	7
21	Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prevention Research, 2018, 11, 4-15.	1.5	15
22	Precision-Exercise-Prescription in patients with lung cancer undergoing surgery: rationale and design of the PEP study trial. BMJ Open, 2018, 8, e024672.	1.9	13
23	Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Advances, 2018, 2, 381-389.	5.2	45
24	Diverse Non-genetic, Allele-Specific Expression Effects Shape Genetic Architecture at the Cellular Level in the Mammalian Brain. Neuron, 2017, 93, 1094-1109.e7.	8.1	34
25	A Phase II Randomized Placebo-Controlled Trial of Oral <i>N</i> -acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress <i>In Vivo</i> . Cancer Prevention Research, 2017, 10, 36-44.	1.5	20
26	The Effect of Previsit Education in Breast Cancer Patients: A Study of a Shared-decision-making Tool. American Surgeon, 2016, 82, 259-265.	0.8	7
27	Reduction in nevus biopsies in patients monitored by total body photography. Journal of the American Academy of Dermatology, 2016, 75, 135-143.e5.	1.2	39
28	Factors associated with early adoption of the HPV vaccine in US male adolescents include Hispanic ethnicity and receipt of other vaccines. Preventive Medicine Reports, 2016, 4, 98-102.	1.8	13
29	Long-term health effects among testicular cancer survivors. Journal of Cancer Survivorship, 2016, 10, 1051-1057.	2.9	23
30	Clinical outcomes associated with evolving treatment modalities and radiation techniques for baseâ€ofâ€tongue carcinoma: thirty years of institutional experience. Cancer Medicine, 2015, 4, 651-660.	2.8	12
31	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 2015, 15, 15.	2.8	35
32	Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecologic Oncology, 2015, 136, 521-528.	1.4	38
33	Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. Journal of Cancer Survivorship, 2015, 9, 115-125.	2.9	47
34	Expanding Access to BRCA1/2 Genetic Counseling with Telephone Delivery: A Cluster Randomized Trial. Journal of the National Cancer Institute, 2014, 106, dju328-dju328.	6.3	105
35	A Population-Based Study of Childhood Cancer Survivors' Body Mass Index. Journal of Cancer Epidemiology, 2014, 2014, 1-10.	1.1	13
36	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology, 2014, 9, 195-204.	3.6	20

3

#	Article	IF	Citations
37	Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. Journal of Cancer Survivorship, 2014, 8, 60-69.	2.9	74
38	Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. Hpb, 2014, 16, 670-676.	0.3	48
39	Isolation of Circulating MicroRNAs from Microvesicles Found in Human Plasma. Methods in Molecular Biology, 2014, 1102, 641-653.	0.9	29
40	Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theoretical Biology and Medical Modelling, 2014, 11, 34.	2.1	16
41	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	1.9	27
42	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 316-320.	1.9	5
43	A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 2013, 79, 307-311.	2.0	23
44	Serum Osteopontin and Tissue Inhibitor of Metalloproteinase 1 as Diagnostic and Prognostic Biomarkers for Pancreatic Adenocarcinoma. Pancreas, 2013, 42, 193-197.	1.1	86
45	Feasibility and Acceptability of a Tai Chi Chih Randomized Controlled Trial in Senior Female Cancer Survivors. Integrative Cancer Therapies, 2013, 12, 464-474.	2.0	36
46	Selenium for the Prevention of Cutaneous Melanoma. Nutrients, 2013, 5, 725-749.	4.1	37
47	Agreement in Risk Prediction Between the 21â€Gene Recurrence Score Assay (Onco type DX®) and the PAM50 Breast Cancer Intrinsic Classifierâ,,¢ in Earlyâ€Stage Estrogen Receptor–Positive Breast Cancer. Oncologist, 2012, 17, 492-498.	3.7	71
48	EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genetics, 2012, 205, 304-312.	0.4	34
49	Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genetics, 2012, 205, 391-404.	0.4	31
50	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. BMC Medical Genomics, 2012, 5, 44.	1.5	250
51	A Genome-Wide Study Replicates Linkage of 3p22-24 to Extreme Longevity in Humans and Identifies Possible Additional Loci. PLoS ONE, 2012, 7, e34746.	2.5	19
52	Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: The national experience. Liver Transplantation, 2012, 18, 423-433.	2.4	48
53	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC) Journal of Clinical Oncology, 2012, 30, 308-308.	1.6	0
54	A Decade of Melanomas: Identification of Factors Associated with Delayed Detection in an Academic Group Practice. Dermatologic Surgery, 2011, 37, 1620-1630.	0.8	13

#	Article	IF	CITATIONS
55	Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. Journal of Clinical Bioinformatics, 2011, 1, 37.	1.2	20
56	Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell, 2011, 19, 441-455.	16.8	452
57	Awareness and Preferences Regarding <i>BRCA1/2</i> Genetic Counseling and Testing Among Latinas and Nonâ€Latina White Women at Increased Risk for Hereditary Breast and Ovarian Cancer. Journal of Genetic Counseling, 2011, 20, 625-638.	1.6	41
58	Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. Hpb, 2010, 12, 352-358.	0.3	13
59	Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2605-2610.	2.5	55
60	First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. Molecular Therapy, 2010, 18, 442-446.	8.2	244
61	Use of Oral <i>N</i> -Acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress: Towards a Novel Paradigm for Melanoma Chemoprevention. Clinical Cancer Research, 2009, 15, 7434-7440.	7.0	42
62	A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 214-219.	1.1	22
63	Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes and Cancer, 2009, 48, 1-9.	2.8	36
64	Empirical methods for controlling false positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics, 2008, 9, 523.	2.6	190
65	Sampling of melanocytic nevi for research purposes: A prospective, pilot study to determine effect on diagnosis. Journal of the American Academy of Dermatology, 2008, 59, 814-821.	1.2	7
66	American Founder Mutation for Attenuated Familial Adenomatous Polyposis. Clinical Gastroenterology and Hepatology, 2008, 6, 46-52.	4.4	41
67	ONCOGENETIC TREES. Series in Mathematical Biology and Medicine, 2008, , 1-24.	0.1	10
68	Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10149-10154.	7.1	246
69	Population-Based Analysis of Prognostic Factors and Survival in Familial Melanoma. Journal of Clinical Oncology, 2005, 23, 7168-7177.	1.6	91
70	UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis, 2004, 26, 249-257.	2.8	68
71	Clinical germline genetic testing for melanoma Lancet Oncology, The, 2004, 5, 314-319.	10.7	62
72	Estimating an oncogenetic tree when false negatives and positives are present. Mathematical Biosciences, 2002, 176, 219-236.	1.9	48